ABAlexandra Berk

Alexandra Berk

*This is an algorithmically generated author record based on publicly available information.

Alexandra Berk has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Study Design to Harmonize Patient-Reported Outcomes Across Data Sets

    by Brittany A. McKelvey, Alexandra Berk, Lynda Chin, Stacie Hudgens, Ian Kudel, Ronan C. O'HAgan, Amila Patel, Julie Scott, Hillary Stires, Sam Wang, et al.

    PURPOSE: Using patient-reported outcomes (PROs) provides important insights from the patient's perspective and can be valuable to monitor and manage treatment-related adverse events during cancer treatment. Additionally, the digital administration of PROs (electronic PROs [ePROs]) provides real-time updates to clinical care teams on treatment-related symptoms in-between clinic visits. However, given the variability in the methodology and timing of the data collection, using and harmonizing these data across different systems remains challenging. Identifying data elements to capture and operating procedures for harmonization across ePRO tools will expedite efforts to generate relevant and robust data on use of ePRO data in clinical care. METHODS: Friends of Cancer Research assembled a consortium of project partners from key health care sectors to align on a framework for ePRO data capture across ePRO tools and assessment of the impact of ePRO data capture on patient outcomes. RESULTS: We identified challenges and opportunities to align ePRO data capture across ePRO tools and aligned on key data elements for assessing the impact of ePRO data capture on patient care and outcomes. Ultimately, we proposed a study protocol to leverage ePRO data for symptom and adverse event management to measure real-world effectiveness of ePRO tool implementation on patient care and outcomes. CONCLUSION: This work provides considerations for harmonizing ePRO data sets and a common framework to align across multiple ePRO tools to assess the value of ePROs for improving patient outcomes. Future efforts to interpret evidence and evaluate the impact of ePRO tools on patient outcomes will be aided by improved alignment across studies.


  • Patient perspective: Financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma

    by Jessica M. Keilson, Stacie Lindsey, Melinda Bachini, Caroline R. Medin, Alexandra Berk, Sophia Cornew, Shishir K. Maithel


  • Open Access

    Abstract 4088: A novel real world clinico-genomics data platform identifies breast cancer histologic and molecular characteristics as candidate predictors for time to distant metastasis

    by Amanda Nottke, Anthony B. Cardillo, Hana E. Littleford, Lisandra West-Odell, Alexandra Berk

    Introduction: Currently, the NCCN guidelines for invasive breast cancer (BC) surveillance are the same regardless of tumor pathology. The length of time between initial diagnosis and documented distant metastasis based on tumor subtypes has not been well-studied in real-world settings, which means that for any given patient, generalized screening recommendations may be either too stringent or too relaxed. Here, we report how tumor histologic and molecular characteristics analyzed from a real-world data platform correlate with the average time to distant recurrence. This information can guide more personalized surveillance for BC patients. Methods: Ciitizen (a wholly owned subsidiary of Invitae) leverages HIPAA right of access on behalf of patients to collect their medical records, extracts relevant clinical information into a standardized and validated longitudinal dataset, and - with their consent - enables research use of this data. From our current invasive BC cohort (n=1011), we identified a subcohort who were diagnosed at Stage I-III with associated histology and/or molecular characterization, then ultimately went on to develop distant metastases (n=195 cases involving 321 sites: bone, brain, liver, and/or lung). We calculated time from initial diagnosis to confirmation of distant metastasis at each site, and statistically analyzed differences using pooled hypothesis testing. Results: In addition to finding expected associations between molecular type and site(s) of metastasis, i.e. bone and brain more common in Hormone Receptor Positive (HR+) subtypes vs HR-, we also characterized the average time to distant metastasis (TDM) to identify other statistically significant associations: Molecular Type: HR-/HER2- (n=30) has an average TDM of 1124 days, which is significantly faster than HR+/HER2- (2224 days; n=197) and HR+/HER2+ (2159 days; n=32) (p=0.0043). BRCA: Individuals with BRCA1/2 pathogenic germline variants have an average TDM of 1043 days (n=15), significantly earlier than individuals with normal BRCA1/2 (2238 days; n=179) (p Citation Format: Amanda Nottke, Anthony B. Cardillo, Hana E. Littleford, Lisandra West-Odell, Alexandra Berk. A novel real world clinico-genomics data platform identifies breast cancer histologic and molecular characteristics as candidate predictors for time to distant metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4088.